Floatz logo

Telomerase: 540-548 Peptide Vaccine

Unspecified Adult Solid Tumor, Protocol Specific

National Cancer Institute (NCI)vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Unspecified Adult Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
DEXAMETHASONE
Alliance for Clinical Trials in Oncology
Phase 3BBB
ETOPOSIDE
University of California, Davis
Phase 2/3BBB
Irinotecan
University of Chicago
Phase 2BBB

View all 50 →

Same molecule, other indications

Telomerase: 540-548 Peptide Vaccine is also rated in:

cutaneous melanomaDormant
B
Indicative ·
57 / 100
View asset →
central nervous system neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
gastrointestinal stromal tumorDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →